eCite Digital Repository

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-Β

Citation

Simpson-Yap, S and Pirmani, A and De Brouwer, E and Peeters, LM and Geys, L and Parciak, T and Helme, A and Hillert, J and Moreau, Y and Edan, G and Spelman, T and Sharmin, S and McBurney, R and Schmidt, H and Bergmann, A and Braune, S and Stahmann, A and Middleton, R and Salter, A and Bebo, B and van der Walt, A and Butzkueven, H and Ozakbas, S and Karabudak, R and Boz, C and Alroughani, R and Rojas, JI and van der Mei, I and Sciascia do Olival, G and Magyari, M and Alonso, R and Nicholas, R and Chertcoff, A and Zabalza, A and Arrambide, G and Nag, N and Descamps, A and Costers, L and Dobson, R and Miller, A and Rodrigues, P and Prckovska, V and Comi, G and Kalincik, T, Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-Β, Multiple Sclerosis and Related Disorders, 66 Article 104072. ISSN 2211-0348 (2022) [Refereed Article]

Copyright Statement

2022 Elsevier B.V.

DOI: doi:10.1016/j.msard.2022.104072

Abstract

Background: Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS.

Results: Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs.

Conclusions: In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS.

Item Details

Item Type:Refereed Article
Keywords:COVID-19, multiple sclerosis, Interferon-β, disease modifying therapy
Research Division:Health Sciences
Research Group:Epidemiology
Research Field:Epidemiology not elsewhere classified
Objective Division:Health
Objective Group:Clinical health
Objective Field:Prevention of human diseases and conditions
UTAS Author:Simpson-Yap, S (Dr Steve Simpson JR)
UTAS Author:van der Mei, I (Professor Ingrid van der Mei)
ID Code:154321
Year Published:2022
Deposited By:Menzies Institute for Medical Research
Deposited On:2022-11-23
Last Modified:2022-12-07
Downloads:0

Repository Staff Only: item control page